media – Page 638 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Australia’s second largest state edges towards permitting euthanasia

The parliament of Australia’s second largest state passed legislation on Friday to allow terminally ill patients to seek medical help to end their lives, a bill that is expected to act as a catalyst for the rest of the country to adopt similar laws.
- Source: reuters
- 568
- October 20, 2017
catalyst euthanasia Market Views Policy
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy

Synthetic gene circuits that only trigger powerful, tumor-specific immune responses when they detect certain disease markers may help immunotherapies to fight cancer more effectively, according to a new study.
- Source: medicalnewstoday
- 700
- October 20, 2017
cancer immunotherapies Synthetic gene
Broken Bones Mended With Stem Cells And Plastic

New bone tissue grown from patients' own stem cells that attach themselves to an implanted, rigid lightweight plastic "scaffolding" which gradually degrades and is replaced as new bone grows, could soon be healing shattered limbs, according to a new research report.
- Source: medicalnewstoday
- 687
- October 20, 2017
bone Researches stem cells
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response.
- Source: Finance
- 667
- October 20, 2017
immune Market Views mRNA vaccine
Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained.
- Source: finance.yahoo
- 617
- October 20, 2017
diabetes FDA New Approvals semaglutide
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA

Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Source: Businesswire
- 691
- October 20, 2017
B-cell lymphoma CAR–T FDA Market Views Yescarta
H7N9 influenza is both lethal and transmissible in animal model for flu

For the first time, Kawaoka says, his team has identified an influenza virus strain that is both transmissible between ferrets (the best animal model proxy for human influenza infections) and lethal, both in the animal originally infected and in otherwise healthy ferrets in close contact with these infected animals.
- Source: Medicalxpress
- 989
- October 20, 2017
H7N9 Researches
China’s Cardiovascular Drugs Import and Export Report

Cardiovascular drugs are medicines used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and strokes, whose therapeutic effects aim to improve cardiac functions, regulate blood flow of heart and change the circulatory system of blood distribution among other things.
- Source: Ddu
- 1,580
- October 19, 2017
cardiovascular Market Reports
Genetic testing startup Prenetics raised $40M in Series B round led by Alibaba’s Hong Kong fund and Beyond Ventures

Genetic testing startup Prenetics has raised $40 million in a Series B funding round led by Hong Kong-based venture capital fund Beyond Ventures and the Alibaba Hong Kong Entrepreneurs Fund.
- Source: Mastsea
- 568
- October 19, 2017
Artificial Intelligence Market Views Series
GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect Shingrix

Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's prescription for growth at the drugmaker.
- Source: fiercepharma
- 617
- October 19, 2017
New Approvals shingles vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.